AIMS MEDICAL has been selected as one of the ten innovative solutions in the first INNOPASS call, part of the Programme for Access to Innovation in the Catalan Health System (PASS).
This initiative aims to facilitate real adoption and scalability of innovative solutions within the public health system, reducing barriers, shortening timelines, and providing clear implementation pathways.
The programme is promoted by Biocat, together with the Servei Català de la Salut (CatSalut) and the Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), with the collaboration of the TIC Salut i Social Foundation. It responds to a shared challenge within the innovation ecosystem: the main barrier is no longer technology itself, but adoption, integration, and scaling within a complex public system.
The selected solutions—most of them with high technological maturity (TRL 7–8), clinical results, pilot projects, and cost-effectiveness studies—highlight the need for structured clinical and economic evidence, alignment with public procurement models, and equitable adoption across the territory. In this context, INNOPASS offers personalised support to help structure evidence, anticipate regulatory requirements, and connect with key stakeholders in the Catalan health system.
For AIMS MEDICAL, the programme focuses on scaling its dysphagia screening tool for older hospitalised patients, with the goal of extending its clinical impact across healthcare centres throughout Catalonia and contributing to safer, more efficient, and more equitable care.
Participation in INNOPASS reinforces AIMS MEDICAL’s commitment to generating real-world clinical impact and to embedding innovation into routine clinical practice beyond isolated pilot projects.